000K utf8 1100 2023$c2023-05-11 1500 eng 2050 urn:nbn:de:gbv:27-dbt-20230607-125342-008 2051 10.3390/jcm12103410 3000 Adam, Luise 3010 Bano, Arjola 3010 Bein, Simone 3010 Borozadi, Meisam K. 3010 Dopheide, Jörn F. 3010 Drexel, Heinz 3010 Muka, Taulant 3010 Strickler, Eva 4000 Prognostic Role of Polyvascular Involvement in Patients with Symptomatic Peripheral Artery Disease [Adam, Luise] 4060 11 Seiten 4209 Background: Statin therapy is recommended for patients with peripheral artery disease (PAD). However, PAD patients with polyvascular (PV) extent remain threatened by an increased residual cardiovascular (CV) risk. Purpose: To investigate the association of prescribed statin therapy and mortality in PAD patients with or without PV extent. Methods: A single-center retrospective longitudinal observational study originating from a consecutive registry with 1380 symptomatic PAD patients over a mean observational time of 60 ± 32 months. The association of atherosclerotic extent and statin use (PAD, plus one additional region (CAD or CeVD, [+1 V]), +2 vascular regions (+CAD and CeVD [+2 V]) with the risk of all-cause mortality was evaluated using Cox proportional hazard models adjusted for potential confounding factors. Results: The mean age of the study’s participants was 72.0 ± 11.7 years, with 36% being female. PAD patients with PV extent [+1 V] and [+2 V] were older and suffered from diabetes, hypertension, or dyslipidemia more often; they, too, had more severely impaired kidney function (all p < 0.0001) compared to patients with PAD only. PAD patients with PV [+1 V] and [+2 V] received better statin medication and reached the recommended LDL-C target compared to PAD-only patients ( p < 0.001). Despite better statin treatment, the rate of all-cause mortality was higher in PV patients than in PAD-only patients (PAD only: 13%; [+1 V]: 22%; [+2 V]: 35%; p < 0.0001). Conclusion: PV patients receive better statin therapy than PAD-only patients but nevertheless still have higher mortality rates. Future studies are needed to explore whether more aggressive LDL-lowering treatment for PAD patients may be translated into better prognosis. 4950 https://doi.org/10.3390/jcm12103410$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:27-dbt-20230607-125342-008$xR$3Volltext$534 4961 https://www.db-thueringen.de/receive/dbt_mods_00057544 5051 610 5550 peripheral artery disease 5550 polyvascular disease 5550 statin therapy